Ƶ

Object moved to here.

Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence | Research, Methods, Statistics | JAMA | Ƶ

Ƶ

[Skip to Navigation]
Sign In

This keynote presentation by Amy P. Abernethy, MD, PhD, was recorded at a JAMA Summit focusing on the clinical trials enterprise and how it can be fixed. Originally recorded October 11, 2023.

1.
Angus DC, Huang AJ, Lewis RJ, et al; JAMA Summit on Clinical Trials Participants. The integration of clinical trials with the practice of medicine: repairing a house divided. Ѵ. Published online June 3, 2024. doi:
2.
Califf RM. Now is the time to fix the evidence generation system. Clin Trials. 2023;20(1):3-12. doi:
3.
Embi PJ, Richesson R, Tenenbaum J, et al; members of 2016 AMIA Policy Invitational Planning Committee. Reimagining the research-practice relationship: policy recommendations for informatics-enabled evidence-generation across the US health system. JAMIA Open. 2019;2(1):2-9. doi:
4.
Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49-58. doi:
5.
Schilsky RL, Currier J, Gilfillan RJ, et al. Enhancing Post-Market Evidence Generation for Medical Products. US Food and Drug Administration. Published December 2023. Accessed January 16, 2024.
6.
Fanaroff AC, Califf RM, Lopes RD. High-quality evidence to inform clinical practice. Գ. 2019;394(10199):633-634. doi:
7.
Fanaroff AC, Califf RM, Windecker S, Smith SC Jr, Lopes RD. Levels of evidence supporting American College of Cardiology/American Heart Association and European Society of Cardiology guidelines, 2008-2018. Ѵ. 2019;321(11):1069-1080. doi:
8.
Nazareth T, Ko JJ, Sasane R, et al. Outcomes-based contracting experience: research findings from US and European stakeholders. J Manag Care Spec Pharm. 2017;23(10):1018-1026. doi:
9.
Farmer SA, Fleisher LA, Blum JD. The transitional coverage for emerging technologies pathway-enhancing innovation while establishing patient safeguards. Ѵ Health Forum. 2023;4(8):e232780. doi:
10.
Fleisher LA. Driving medical innovation-focusing on the evidence to inform best care for patients. Ѵ Cardiol. 2023;8(12):1109-1110. doi:
11.
Clinical trial considerations to support accelerated approval of oncology therapeutics. US Food and Drug Administration. March 27, 2023. Accessed May 20, 2024.
12.
Expedited programs for regenerative medicine therapies for serious conditions: guidance for industry. US Food and Drug Administration. Published February 2019. Accessed May 20, 2024.
13.
Trusted exchange framework and common agreement (TEFCA). Office of the National Coordinator for Health Information Technology. Updated April 22, 2024. Accessed May 20, 2024.
14.
Real-world evidence. US Food and Drug Administration. February 5, 2023. Accessed May 20, 2024.
15.
Observational Health Data Sciences and Informatics. Standardized data: the OMOP common data model. 2024. Accessed May 20, 2024.
16.
PCORnet, the National Patient-Centered Clinical Research Network: program overview. Patient-Centered Outcomes Research Institute. Updated September 6, 2023. Accessed May 20, 2024.
17.
About the Food and Drug Administration sentinel initiative. Sentinel. 2007. Accessed May 20, 2024.
18.
National COVID cohort collaborative (N3C). US Dept of Health and Human Services. 2024. Accessed June 27, 2024.
19.
Han J, Chen K, Fang L, et al. Improving the efficacy of the data entry process for clinical research with a natural language processing-driven medical information extraction system: quantitative field research. JMIR Med Inform. 2019;7(3):e13331. doi:
20.
Considerations for the design and conduct of externally controlled trials for drug and biological products. US Food and Drug Administration. January 31, 2023. Accessed May 20, 2024.
21.
Registry trials. Clinical Trials Transformation Initiative. Published December 13, 2019. Accessed March 1, 2024.
22.
Gliklich RE, Dreyer NA, Leavy MB, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. 3rd ed. Agency for Healthcare Research and Quality. Published April 2014. Accessed May 20, 2024.
23.
Lerro CC, Bradley MC, Forshee RA, Rivera DR. The bar is high: evaluating fit-for-use oncology real-world data for regulatory decision making. JCO Clin Cancer Inform. 2024;8:e2300261. doi:
24.
Canham S, Ohmann C. A metadata schema for data objects in clinical research. հ. 2016;17(1):557. doi:
25.
Bönisch C, Kesztyüs D, Kesztyüs T. Harvesting metadata in clinical care: a crosswalk between FHIR, OMOP, CDISC and openEHR metadata. Sci Data. 2022;9(1):659. doi:
26.
PROV-DM: the PROV data model. W3C. April 13, 2013. Accessed May 20, 2024.
27.
The All of Us consent process. All of Us Research Program. Last reviewed July 16, 2021. Accessed June 27, 2024.
28.
Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. Hastings Cent Rep. 2013;43(S1):S16-S27. doi:
29.
Califf RM, Faden R, Kass N, Morain S, Crane M. Challenges in the ethics and implementation of learning health care systems. Am J Bioeth. 2023;23(8):1-4. doi:
30.
Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials. 2015;12(5):436-441. doi:
31.
Woodcock J, Araojo R, Thompson T, Puckrein GA. Integrating research into community practice—toward increased diversity in clinical trials. N Engl J Med. 2021;385(15):1351-1353. doi:
32.
Advancing Clinical Trial Readiness (ACTR) initiative description. American Rescue Plan Act for Health. 2023. Accessed May 20, 2024.
33.
Electronic source data in clinical investigations: guidance for industry. US Food and Drug Administration. September 2013. Accessed May 20, 2024.
34.
Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry. US Food and Drug Administration. August 30, 2023. Accessed May 20, 2024.
35.
Rawson K. US FDA regulatory affairs reorg to include inspectors trained in real-world evidence, Califf says. Pink Sheet Citeline Regulatory. Published October 20, 2023. Accessed March 1, 2024.
36.
(Proposed) coverage with evidence development. CMS.com. Accessed March 1, 2024.
37.
International Council for Harmonisation. Final concept paper: ICH E6 (R3) guideline for good clinical practice annex-2. April 28, 2023. Accessed May 20, 2024.
38.
Project pragmatica: advancing evidence generation for oncology medical products. US Food and Drug Administration. February 8, 2024. Accessed May 20, 2024.
39.
Recovery trial. Accessed May 20, 2024.
Special Communication
Integrating Clinical Trials and Practice
ܲܲ5, 2024

Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence

Author Affiliations
  • 1Verily Life Sciences, South San Francisco, California
  • 2Center for Biostatistics & Qualitative Methodology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 3Bakar Computational Health Sciences Institute, University of California, San Francisco
  • 4Center for Data-Driven Insights and Innovation, University of California Health, Oakland
  • 5Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  • 6Departments of Surgery and Radiology and Institute for Health Policy Studies, University of California, San Francisco
  • 7Anesthesiology and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 8Biogen, Boston, Massachusetts
  • 9Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • 10Yale University School of Medicine, New Haven, Connecticut
  • 11National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research Programme, London, United Kingdom
  • 12Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom
  • 13Highlander Health, Dallas, Texas
JAMA. Published online August 5, 2024. doi:10.1001/jama.2024.0268
Abstract

Importance The ways in which we access, acquire, and use data in clinical trials have evolved very little over time, resulting in a fragmented and inefficient system that limits the amount and quality of evidence that can be generated.

Observations Clinical trial design has advanced steadily over several decades. Yet the infrastructure for clinical trial data collection remains expensive and labor intensive and limits the amount of evidence that can be collected to inform whether and how interventions work for different patient populations. Meanwhile, there is increasing demand for evidence from randomized clinical trials to inform regulatory decisions, payment decisions, and clinical care. Although substantial public and industry investment in advancing electronic health record interoperability, data standardization, and the technology systems used for data capture have resulted in significant progress on various aspects of data generation, there is now a need to combine the results of these efforts and apply them more directly to the clinical trial data infrastructure.

Conclusions and Relevance We describe a vision for a modernized infrastructure that is centered around 2 related concepts. First, allowing the collection and rigorous evaluation of multiple data sources and types and, second, enabling the possibility to reuse health data for multiple purposes. We address the need for multidisciplinary collaboration and suggest ways to measure progress toward this goal.

×